Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of DC-853 (Simepdekinra) in Healthy Participants
NCT06937411Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2023
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of simepdekinra in plaque psoriasis (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs). Started Feb 2023; status: completed.
02
Drugs
simepdekinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06937411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06937411.